DuoTrav® Eye Drops As Replacement Therapy Program

Alcon Research128 enrolled

Overview

To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

128

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

DuoTravDRUG

DuoTrav Eye Drops

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction Exclusion Criteria: * None

Locations (1)

Contact Alcon for Trial Locations

Beijing, China

Outcomes

Primary Outcomes

Intra Ocular Pressure

Time frame: visit 1, Visits 2-3, Visits 6-8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.